Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

BACKGROUND: Chronic psoriasis may require medication adjustments over time. OBJECTIVES: To evaluate the efficacy/safety of tildrakizumab in subgroups from the reSURFACE studies (N = 1862) that received continuous dosing, higher/lower dosing, treatment interruption/reinitiation and initiation. METHOD...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Dermatol
Hlavní autoři: Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317753/
https://ncbi.nlm.nih.gov/pubmed/31487406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18484
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky